FIELD: chemistry.
SUBSTANCE: claimed invention relates to field of biotechnology, namely to obtaining stable liquid etanercept composition, and can be used in medicine. Liquid composition of etanercept -recombinant sTNFR p75:Fc fusion protein, consisting in fact of etanercept and stabiliser: methionine, lysine and/or histidine, is obtained. Stabiliser is present in quantity from 0.1 to 250 mM.
EFFECT: invention makes it possible to obtain composition with increased etanercept storage stability in comparison with composition, which does not have stabilisers, due to reduction of etanercept by-products, formed as a result of denaturation in the process of storage.
14 cl, 10 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID COMPOSITION OF POLYPEPTIDES CONTAINING FC DOMAIN OF IMMUNOGLOBULIN | 2011 |
|
RU2600847C2 |
| LIQUID COMPOSITION OF AN ANTIBODY AGAINST TNF ALPHA | 2018 |
|
RU2756619C2 |
| HUMAN PARATHYROID HORMONE (PTH) FORMULATIONS AND METHODS FOR PREPARING THEREOF | 2020 |
|
RU2820316C1 |
| STABLE LIQUID PHARMACEUTICAL PREPARATIONS OF FUSED PROTEIN TNFR: Fc | 2012 |
|
RU2614257C2 |
| STABLE AQUEOUS COMPOSITIONS OF PROTEIN MIA/CD-RAP | 2011 |
|
RU2588658C2 |
| LIQUID FORMULATION OF LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2013 |
|
RU2671576C2 |
| STABLE AQUEOUS PROTEIN COMPOSITIONS OF MIA/CD-RAP | 2011 |
|
RU2739078C2 |
| FLUID FORMULATION OF FOLLICLE-STIMULATING HORMONE | 2011 |
|
RU2553375C2 |
| STABLE PHARMACEUTICAL COMPOSITION OF TNFR: FC FUSION PROTEIN | 2013 |
|
RU2664691C2 |
| FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
